Top China Stocks To Invest In 2018

(Published Feb. 23 by Bob Ciura)

Shares of consumer products company Nu Skin Enterprises (NYSE:NUS) crashed 11% after the company missed analyst expectations on both sales and earnings per share for the fourth quarter.

Nu Skin has struggled mightily over the past three years. In January 2014, the company was hit with an investigation by Chinese regulatory authorities into the firm’s business practices.

But it’s not all bad news – Nu Skin’s earnings are growing, and the stock has a 3% dividend yield.

Plus, Nu Skin raised its dividend by 1.4% after providing its earnings report.

This makes 16 years in a row of annual dividend hikes. Nu Skin is a group of 272 stocks with 10+ years of consecutive dividend increases, known as the Dividend Achievers.

You can see the full Dividend Achievers List here.

Nu Skin has come a long way since the investigation, and has made meaningful strides in turning around the China business.

Top China Stocks To Invest In 2018: Syndax Pharmaceuticals, Inc. (SNDX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was down, falling around 22 percent to $8.634 after the company issued updated results from Phase 2 ENCORE trial of entinostat in combo with KEYTRUDA.

  • [By Logan Wallace]

    Several institutional investors have recently bought and sold shares of the company. BVF Inc. IL acquired a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $28,326,000. Millennium Management LLC grew its position in shares of Syndax Pharmaceuticals by 18.9% during the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock worth $4,525,000 after buying an additional 82,256 shares during the period. Geode Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 17.4% during the 4th quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock worth $1,344,000 after buying an additional 22,803 shares during the period. Crestline Management LP grew its position in shares of Syndax Pharmaceuticals by 55.3% during the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock worth $728,000 after buying an additional 29,607 shares during the period. Finally, State Street Corp grew its position in shares of Syndax Pharmaceuticals by 32.8% during the 2nd quarter. State Street Corp now owns 81,327 shares of the company’s stock worth $1,137,000 after buying an additional 20,106 shares during the period. Institutional investors own 69.55% of the company’s stock.

    TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Rating Lowered to D at TheStreet” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3364448/syndax-pharmaceuticals-sndx-rating-lowered-to-d-at-thestreet.html.

    About Syndax Pharmaceuticals

  • [By ]

    Syndax (SNDX) is developing entinostat, a Class I HDAC inhibitor, for the treatment of solid tumors. Shares popped recently following the release of Syndax’s first quarter earnings results, but a bigger catalyst on the horizon is the upcoming ASCO oncology conference in June. Syndax is due to present updated data from the ENCORE-601 Phase 2 trial in melanoma and lung cancer.

Top China Stocks To Invest In 2018: GlobalSCAPE, Inc.(GSB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Akorn, Inc. (NASDAQ: AKRX) fell 32.7 percent to $13.25 in pre-market trading after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 15.7 percent to $12.30 in pre-market trading. Subsea 7 confirmed a $7.00 per share proposal to acquire Mcdermott, pending termination of merger agreement with CB&I.
    Myomo, Inc. (NYSE: MYO) fell 9 percent to $3.65 in pre-market trading after rising 11.39 percent on Friday.
    Hasbro, Inc. (NASDAQ: HAS) fell 8 percent to $88.36 in pre-market trading after the company reported weaker-than-expected results for its first quarter on Monday.
    SunPower Corporation (NASDAQ: SPWR) fell 7.1 percent to $9.00 in pre-market trading.
    Endeavour Silver Corp. (NYSE: EXK) shares fell 5.9 percent to $2.88 in pre-market trading after declining 3.16 percent on Friday.
    Mattel, Inc. (NASDAQ: MAT) shares fell 5.5 percent to $12.25 in pre-market trading.
    Valeritas Holdings, Inc. (NASDAQ: VLRX) shares fell 5.1 percent to $2.96 in pre-market trading after rising 76.27 percent on Friday.
    GlobalSCAPE, Inc. (NYSE: GSB) fell 5.1 percent to $3.57 in pre-market trading.
    Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) shares fell 4.1 percent to $49.93 in pre-market trading.
    Oasis Petroleum Inc. (NYSE: OAS) fell 4.1 percent to $9.75 in pre-market trading. SunTrust Robinson Humphrey downgraded Oasis Petroleum from Hold to Sell

Top China Stocks To Invest In 2018: Teva Pharmaceutical Industries Limited(TEVA)

Advisors’ Opinion:

  • [By ]

    Cramer was bearish on United States Steel (X) , Teva Pharmaceuticals (TEVA) , Aqua America (WTR) and Mueller Water Products (MWA) .

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By Chris Lange]

    Teva Pharmaceutical Industries Ltd.s (NYSE: TEVA) short interest decreased to 55.84 million from the previous level of 59.40 million. Shares were trading at $17.56, in a 52-week range of $10.85 to $33.82.

  • [By Todd Campbell, Sean Williams, and Brian Feroldi]

    There have been more stock market pops and drops lately and that might have you wondering what healthcare stocks can be bought to take advantage of this volatility. Buying healthcare stocks during periods of volatility can be smart because demand for healthcare products and services usually isn’t discretionary. However, that doesn’t necessarily mean it makes sense to buy every healthcare stock out there. To find out what healthcare stocks it might make sense to buy this month, we asked top Motley Fool investors what companies are on their radar. In their view,Teva Pharmaceutical Industries (NYSE:TEVA), Novacure (NASDAQ:NVCR), and Galapagos (NASDAQ:GLPG)should be at the top of your idea list right now. Read on to find out why.

  • [By Todd Campbell]

    Warren Buffett’s penchant for picking great stocks for Berkshire Hathaway’s (NYSE:BRK-A) (NYSE:BRK-B) portfolio makes his quarterly stock picks must-know news for every long-term investor. Luckily, Buffett is required to file a 13F report with the Securities and Exchange Commission every quarter showing what he’s been buying, and that makes following in his footsteps easier. Last quarter, his top buys were U.S. Bancorp (NYSE:USB),Apple, Inc. (NASDAQ:AAPL), andTeva Pharmaceutical Industries (NYSE:TEVA). Should you buy these stocks for your portfolio, too?

  • [By ]

    Buffett also more than doubled his stake in generic drugmaker Teva Pharmaceuticals (NYSE: TEVA) to 40 million shares. This was a new investment in the fourth quarter and could still be a good entry point for new investors.

Top China Stocks To Invest In 2018: Aegion Corp(AEGN)

Advisors’ Opinion:

  • [By Shane Hupp]

    LSV Asset Management decreased its position in Aegion Corp (NASDAQ:AEGN) by 5.7% in the 1st quarter, HoldingsChannel reports. The fund owned 108,700 shares of the construction company’s stock after selling 6,600 shares during the period. LSV Asset Management’s holdings in Aegion were worth $2,490,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Stephan Byrd]

    Aegion (NASDAQ:AEGN) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Aegion (AEGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top China Stocks To Invest In 2018: Allison Transmission Holdings, Inc.(ALSN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ARP Americas LP lowered its stake in shares of Allison Transmission (NYSE:ALSN) by 8.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,497 shares of the auto parts company’s stock after selling 1,400 shares during the quarter. ARP Americas LP’s holdings in Allison Transmission were worth $566,000 at the end of the most recent quarter.

  • [By Ethan Ryder]

    Allison Transmission (NYSE:ALSN) announced a quarterly dividend on Thursday, May 10th, Zacks reports. Stockholders of record on Monday, May 21st will be given a dividend of 0.15 per share by the auto parts company on Thursday, May 31st. This represents a $0.60 annualized dividend and a dividend yield of 1.40%. The ex-dividend date is Friday, May 18th.

  • [By Stephan Byrd]

    Allison Transmission (NYSE:ALSN) – Investment analysts at Oppenheimer increased their FY2018 earnings per share (EPS) estimates for Allison Transmission in a research note issued on Monday, April 30th. Oppenheimer analyst I. Zaffino now expects that the auto parts company will post earnings of $3.79 per share for the year, up from their previous forecast of $3.32. Oppenheimer also issued estimates for Allison Transmission’s FY2019 earnings at $4.16 EPS.

Top China Stocks To Invest In 2018: USG Corporation(USG)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Warren Buffett likes to hold his stock positions for the long run, and his experience with USG (NYSE:USG) has been typical of his other long-term investments. The Oracle of Omaha started buying shares of the manufacturer of Sheetrock drywall and other building materials back in 2000, accumulating a sizable stake that has ballooned to more than 30% of the company. USG ended up going through bankruptcy in order to get a handle on its asbestos liability claims, but thanks largely to Buffett’s involvement, the building materials company not only survived bankruptcy but also saw share prices soar briefly on hopes that USG would once again fully participate in the then-strong housing boom.

  • [By Jason Hall, George Budwell, and Chuck Saletta]

    And while it may not always work out well to simply copy the moves other investors make, it can pay off to use their buying and selling moves as jumping-off points in your own research. We asked three real-world investors for their insight, and they wrote about two recent Buffett buys ofApple Inc.(NASDAQ:AAPL) andUSG Corporation(NYSE:USG), and a recent Baker Brothers buy ofHeron Therapeutics Inc(NASDAQ:HRTX).

  • [By Stephan Byrd]

    ValuEngine upgraded shares of USG (NYSE:USG) from a buy rating to a strong-buy rating in a report published on Tuesday.

    A number of other research analysts have also recently weighed in on the stock. Credit Suisse Group upgraded shares of USG from an underperform rating to a neutral rating and dropped their target price for the company from $35.00 to $24.00 in a research note on Friday, April 27th. Jefferies Group reiterated a hold rating and issued a $40.00 target price on shares of USG in a research note on Monday, April 23rd. SunTrust Banks boosted their target price on shares of USG from $42.00 to $44.00 and gave the company a hold rating in a research note on Tuesday, April 17th. Buckingham Research boosted their target price on shares of USG from $34.00 to $42.00 and gave the company a neutral rating in a research note on Monday, April 16th. Finally, Nomura boosted their target price on shares of USG from $39.00 to $44.00 and gave the company a neutral rating in a research note on Tuesday, March 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $39.00.

  • [By Jordan Wathen]

    As USG Corporation (NYSE:USG) drags its feet on an offer to sell the company for $42 per share, Berkshire intends to use its 30.8% ownership stake to motivate its top brass to make a deal. Berkshire told Bloomberg it intends to vote its shares against USG’s board members who are up for re-election at this year’s annual meeting, a clear message that Buffett is ready to cash in, even if USG’s management and board are not.